Indian expert group to re-examine spurious drug definitions
This article was originally published in Scrip
India has constituted an expert group to examine the definitions of spurious, adulterated and misbranded drugs in the Drugs and Cosmetic Act and recommend changes to these in the context of "present trade practices followed nationally and internationally".
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.